This report was first published by Endpoints News. To see the original version, click here
Pfizer’s final-stage trial of its long-awaited Lyme disease vaccine missed its primary endpoint, but the drugmaker said it still plans to try to take the experimental shot to regulators for approval.
The company said there had been too few Lyme cases to get a firm result in the trial of the vaccine, known as LB6V.
您已阅读12%（404字），剩余88%（3001字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。